Capricor Therapeutics enters the July 4 week having shed another 24% on the month to $23.21, with a fresh cluster of insider selling landing precisely as the bear thesis continues to play out.
The insider activity is the sharpest new development this week. Both the CFO and General Counsel sold shares on June 22, 24, and 25 — three consecutive trading sessions — at prices between $30.00 and $30.38, collecting a combined $1.5 million in those three days alone. Those sales came at levels well above the current $23.21 close, meaning they sold near the recent range highs before the stock gave back another leg. The net insider flow across 90 days runs to roughly $8.4 million in sales. The pattern is consistent — no purchases, repeated sales from senior officers — and the timing, executed at $30 while the stock now trades at $23, is notable context ahead of the August 6 earnings print.
Short interest remains the dominant structural feature. Bears hold 28.4% of the free float — roughly 13 million shares — up 3.8% on the week and nearly 19% over the past month. That is an ongoing build, not a plateau. The ORTEX short score is 76.7, eased slightly from the 79.5 peak hit on June 30 but still running near its highest sustained level in the tracked history. Days to cover per FINRA data are 13.7. For three consecutive notes this position has been flagged as large and growing; this week the price action has moved further in the bears' favour, with the stock off 24% in the week after the June 27 note warned bears were holding firm.
The borrow market continues to offer a structural contradiction. Despite 28% of the float being short, cost to borrow is just 0.57% — barely above a standard-rate equity. Availability is actually loosening, up 5.9% on the week to 179%, meaning there are nearly two shares available to borrow for every one already borrowed. The 52-week low availability reading was 7% — nowhere near that now. Options positioning offers no additional pressure signal: the put/call ratio is 0.38, right on its 20-day average and near the low end of its annual range. Bears are not paying up to press the position and the options market shows no unusual hedging activity in either direction.
The institutional picture adds one more layer. Suvretta Capital and Tang Capital both added aggressively in Q1, picking up 2.9 million and 1.7 million shares respectively. BlackRock added 571,000 shares, most recently reported as of June 30. These are meaningful long-side accumulations sitting against the 13-million-share short. Point72 trimmed 1 million shares in Q1. Among close peers, SLDB gained 22% on the week and ABEO rose 15%, suggesting the small-cap rare-disease space broadly saw a bid — a tailwind that did not reach CAPR in a meaningful way, with the stock down 24% in the same period.
The Q1 earnings print in May produced a 5% next-day decline and a 16% five-day loss. The next event is August 6. With insider selling concentrated near $30, short interest anchored above 28%, and the stock now trading at $23, the question heading into that print is whether the borrow market finally tightens to reflect the pressure — or whether the loose availability signals there is still runway for the bear position to grow before any squeeze mechanics engage.
See the live data behind this article on ORTEX.
Open CAPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
